| Literature DB >> 21791050 |
Rajesh Ramakrishnan1, Wendong Yu, Andrew P Rice.
Abstract
BACKGROUND: The elongation phase, like other steps of transcription by RNA Polymerase II, is subject to regulation. The positive transcription elongation factor b (P-TEFb) complex allows for the transition of mRNA synthesis to the productive elongation phase. P-TEFb contains Cdk9 (Cyclin-dependent kinase 9) as its catalytic subunit and is regulated by its Cyclin partners, Cyclin T1 and Cyclin T2. The HIV-1 Tat transactivator protein enhances viral gene expression by exclusively recruiting the Cdk9-Cyclin T1 P-TEFb complex to a RNA element in nascent viral transcripts called TAR. The expression patterns of Cyclin T1 and Cyclin T2 in primary monocytes and CD4+ T cells suggests that Cyclin T2 may be generally involved in expression of constitutively expressed genes in quiescent cells, while Cyclin T1 may be involved in expression of genes up-regulated during macrophage differentiation, T cell activation, and conditions of increased metabolic activity To investigate this issue, we wished to identify the sets of genes whose levels are regulated by either Cyclin T2 or Cyclin T1.Entities:
Year: 2011 PMID: 21791050 PMCID: PMC3160394 DOI: 10.1186/1756-0500-4-260
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Figure 1shRNA against Cyclin T2 expressed from a lentiviral vector specifically and efficiently depletes CyclinT2 protein. (A) HeLa cells infected at an m.o.i. of five with lentiviral vectors expressing a shRNA against Cyclin T2 (shRNA T2), Cyclin T1 (shRNA T1) or a control shRNA against a mismatch sequence in Cyclin T1 (shRNA MM). Cultures were analyzed five days post infection by flow cytometry. HeLa cells not treated with any shRNA were used as a control for flow cytometry analysis. The lentiviral vectors express a GFP marker protein. The unfilled region represents GFP background level in non-treated HeLa cells. The percentages of GFP positive cells are indicated. (B) Total RNA was extracted from HeLa cells transduced with shRNA T2 or shRNA MM after five days post infection and analyzed Cyclin T2, Cyclin T1 mRNA by quantitative real time RT-PCR. The fold-change is indicative of the transcript levels in the shRNA T2 treated cells relative to the shRNA MM treated cells after normalization to housekeeping gene, β-actin levels. (C) Immunoblot analysis of cell extracts prepared from HeLa cells transduced for five days with shRNA T2, shRNA T1 or shRNA MM lentiviral vectors. Untransduced HeLa cells (Mock) were used as control. The immunoblots were performed to analyze the levels of Cyclin T2, Cyclin T1, Cdk9, HEXIM1 and β-actin proteins. The band intensity was quantified using ImageJ and presented below each panel.
Figure 2Cyclin T2 depletion does not affect HeLa cell growth. HeLa cells transduced with lentiviral shRNA vectors (shRNA T2, shRNA T1, shRNA MM) for 5 days were sorted by flow cytometry for GFP expression. The sorted (105 cells) cells were plated and MTT cell growth and viability assay was performed on days 0, 3, 7 and 9. Results are expressed as the percentage of viable cells compared with MM control shRNA transduced cells.
Figure 3Validation of microarray data. Total RNA was extracted from four independent HeLa cell infections with indicated shRNA vectors for five days including aliquots of RNA for microarray analysis. Quantitative real-time RT-PCR was carried out to measure the expression level of indicated mRNA. The fold-change was calculated and represents the change in transcript levels in shRNA T2 or T1 infected cells relative to shRNA MM treated cells after normalization to housekeeping gene, GAPDH. Average fold-change from the four independent infections is presented. * p < 0.05, ** p < 0.005, *** p < 0.0005 in a paired t-test.
Figure 4Differential expression of genes following Cyclin T2 or Cyclin T1 knockdown. Heat map of genes differentially expressed in HeLa cells infected with lentiviral shRNA vectors against Cyclin T2 or Cyclin T1 compared to control MM. Up regulated genes are in red and down regulated genes are in green. The insets represent an enlargement of a portion of the heat map.
Figure 5Summary of pairwise comparisons for genes affected in shRNA T2 and shRNA T1 infected HeLa cells. The Venn diagram represents the following individual pairwise comparisons: down regulated genes- shRNA T2 (blue circle) vs. shRNA T1 (orange circle), up regulated genes- shRNA T2 (purple circle) vs. shRNA T1 (green circle) each compared to shRNA MM. Number in parentheses represents the total number of genes whose expression was changed for that comparison. The numbers within each circle represents the genes unique to that comparison. The number in the intersection of the gene sets representing the shared genes whose expression was changed is indicated.
Figure 6KEGG pathway analysis of genes regulated by Cyclin T2 and Cyclin T1. KEGG pathway grouping was done based on z-score following Gene Ontologic analysis of the unique and shared gene sets down regulated following HeLa cell infection with shRNA T2 or shRNA T1 lentiviral vectors compared to cells infected with control shRNA MM vector. The pie charts show over represented pathways for indicated conditions. The z-scores are also presented.
List of genes down regulated upon Cyclin T2 and Cyclin T1 depletion
| Gene name | Gene ID | Gene identifier | Probe ID | Chromosome | Fold-change | p-value |
|---|---|---|---|---|---|---|
| HSPB3 | NM_006308 | 206375_s_at | 5 | -3.12 | 0.0368 | |
| GPR137B | NM_003272 | 204137_at | 1 | -2.3 | 0.0251 | |
| ABCA1 | NM_005502 | 203504_s_at | 9 | -2.1 | 0.0336 | |
| ANKRD12 | X80821 | 216563_at | 18 | -2.06 | 0.0166 | |
| ATXN1 | AW235612 | 203231_s_at | 6 | -2.04 | 0.0111 | |
| CORO6 | NM_032854 | 1552301_a_at | 17 | -2.04 | 0.0330 | |
| GAS1 | NM_002048 | 204457_s_at | 9 | -2.02 | 0.0303 | |
| ATG16L1 | NM_017974 | 220521_s_at | 2 | -1.95 | 0.0375 | |
| HEXIM1 | NM_006460 | 202815_s_at | 17 | -1.94 | 0.0482 | |
| CACNB2 | NM_000724 | 207776_s_at | 10 | -1.85 | 0.0178 | |
| CXCL14 | NM_004887 | 218002_s_at | 5 | -3.55 | 0.0403 | |
| TMPRSS3 | AB038160 | 223949_at | 21 | -2.59 | 0.0361 | |
| ANKRD29 | AI307802 | 238332_at | 18 | -2.36 | 0.0433 | |
| FKBP1B | NM_004116 | 206857_s_at | 2 | -2.16 | 0.0108 | |
| SDCBP | NM_005625 | 203231_s_at | 8 | -2.09 | 0.0366 | |
| DDX18 | NM_006773 | 205763_s_at | 2 | -1.9 | 0.0217 | |
| EIF4EBP2 | U88989 | 224653_at | 10 | -1.89 | 0.0168 | |
| STK38 | NM_007271 | 1553117_a_at | 6 | -1.68 | 0.0196 | |
| CCNG2 | AW134535 | 202769_at | 4 | -1.65 | 0.0129 | |
| S100A4 | NM_002961 | 203186_s_at | 1 | -1.62 | 0.0117 | |
Genes with greatest down regulation specific to Cyclin T2 or Cyclin T1 depletion. The 10 genes with greatest decrease in expression following Cyclin T2 or Cyclin T1 depletion are listed (p 0.05). All fold-changes are relative to MM control. Minimum expression level of genes in MM control was arbitrarily chosen as 3.0.
List of genes commonly down regulated by Cyclin T2 or Cyclin T1 depletion
| Gene name | Gene ID | Gene identifier | Probe ID | Chromosome | Fold-change | p-value | |
|---|---|---|---|---|---|---|---|
| AKR1C2 | U05598 | 209699_x_at | 10 | -2.84 | -2.23 | 0.0153 | |
| BMP2 | AA583044 | 205289_at | 20 | -2.46 | -2.18 | 0.0239 | |
| FOXQ1 | AI676059 | 227475_at | 6 | -1.98 | -2.18 | 0.0415 | |
| CASP1 | U13699 | 211367_s_at | 11 | -1.95 | -1.85 | 0.048914 | |
| DUSP16 | AB051487 | 224832_at | 12 | -1.94 | -1.32 | 0.0407 | |
| PBXIP1 | AI935162 | 214177_s_at | 1 | -1.90 | -2.08 | 0.0185 | |
| BRD9 | NM_024786 | 1552283_s_at | 5 | -1.82 | -1.7 | 0.007266 | |
| TCF7L1 | NM_031283 | 221016_s_at | 2 | -1.81 | -1.8 | 0.010119 | |
| PXDN | D86983 | 212013_at | 2 | -1.76 | -1.83 | 0.0127 | |
| AGPAT3 | BC004219 | 223184_s_at | 21 | -1.61 | -1.79 | 0.01225 | |
Genes commonly down regulated when either Cyclin T2 or Cyclin T1 is depleted. The 10 genes with greatest decrease in expression following Cyclin T2 or Cyclin T1 depletion are listed (p ≤ 0.05). All fold-changes are relative to MM control. Minimum expression level of genes in MM control was arbitrarily chosen as 3.0.
Gene Ontology (GO) analysis of the gene list based on z-score
| Ontology | List | Array | z-score |
|---|---|---|---|
| 14 | 566 | 3.38 | |
| 8 | 331 | 2.45 | |
| 7 | 241 | 2.83 | |
| 6 | 204 | 2.65 | |
| 6 | 167 | 3.22 | |
| 6 | 109 | 4.56 | |
| 5 | 176 | 2.33 | |
| 4 | 140 | 2.09 | |
| 4 | 66 | 3.98 | |
| 4 | 126 | 2.33 | |
| 4 | 128 | 2.3 | |
| 3 | 69 | 2.68 | |
| 3 | 93 | 2.05 | |
| 2 | 22 | 3.69 | |
| 2 | 43 | 2.31 | |
| 2 | 34 | 2.75 | |
| 2 | 17 | 4.32 | |
| 2 | 40 | 2.44 | |
| 2 | 13 | 5.05 | |
| 2 | 24 | 3.49 | |
| 2 | 46 | 2.18 | |
| 2 | 30 | 3.01 | |
| 2 | 37 | 2.59 | |
| 2 | 46 | 2.18 | |
| 2 | 44 | 2.26 | |
| 2 | 44 | 2.26 | |
| 2 | 39 | 2.49 | |
| 2 | 7 | 7.12 | |
| 178 | 6465 | -2.45 | |
| 158 | 6076 | -3.31 | |
| 64 | 2908 | -3.24 | |
| 43 | 1038 | 2.05 | |
| 28 | 555 | 2.72 | |
| 27 | 551 | 2.51 | |
| 26 | 524 | 2.53 | |
| 26 | 525 | 2.52 | |
| 17 | 342 | 2.04 | |
| 17 | 343 | 2.02 | |
| 15 | 291 | 2.06 | |
| 14 | 247 | 2.36 | |
| 13 | 235 | 2.18 | |
| 11 | 197 | 2.04 | |
| 10 | 160 | 2.32 | |
| 10 | 174 | 2.04 | |
| 9 | 139 | 2.32 | |
| 9 | 130 | 2.54 | |
| 4 | 37 | 2.72 | |
| 3 | 31 | 2.12 | |
| 3 | 464 | -3.11 | |
| 3 | 383 | -2.66 | |
| 2 | 17 | 2.07 | |
| 2 | 8 | 3.58 | |
| 2 | 7 | 3.89 | |
| 2 | 16 | 2.17 | |
| 2 | 17 | 2.07 | |
| 25 | 3058 | 2.04 | |
| 24 | 2840 | 2.17 | |
| 11 | 748 | 3.33 | |
| 10 | 696 | 3.08 | |
| 9 | 631 | 2.89 | |
| 9 | 655 | 2.77 | |
| 9 | 627 | 2.91 | |
| 9 | 540 | 3.42 | |
| 8 | 524 | 2.93 | |
| 8 | 551 | 2.77 | |
| 8 | 499 | 3.09 | |
| 6 | 147 | 5.63 | |
| 6 | 342 | 2.91 | |
| 2 | 63 | 2.72 | |
| 2 | 76 | 2.37 | |
| 2 | 37 | 3.88 | |
| 2 | 93 | 2.01 | |
A GO analysis of the gene sets unique (192 and 531) and shared (100) to Cyclin T2 and Cyclin T1 depletion, respectively, was carried out and grouped based on z-score. Only GO categories that were over represented with at least 2 genes were considered. The "List" value is the number of affected genes from the gene list in the group. The "Array" value shows the total number of genes on the microarray that are in this gene ontology. The "z-score" is the expected number of genes in a GO term, subtracted from the observed number of genes. This value is divided by the standard deviation of the observed number of genes.
Functional annotation of genes associated with disease
| Condition | Disease/Processes | Genes |
|---|---|---|
| Aging | Fas (TNF receptor superfamily, member 6) | |
| N-acteyltransferase 1 (Arylamine N-acteyltransferase) | ||
| ATP-binding cassette, sub-family A (ABC1), member 1 | ||
| Superoxide dismutase 2, mitochondrial | ||
| Hemochromatosis | ||
| HIV-1 biology | Cyclin dependent kinase 9 (Cdk9) | |
| Cyclin T1 | ||
| Granulin | ||
| Major histocompatibility complex, Class II, DM alpha | ||
| Tubulin, beta 6 | ||
| Dementia | Amyloid beta (A4) precursor protein (peptidase Nexin-II, Alzheimer disease) | |
| Very low density lipoprotein receptor | ||
| Estrogen receptor 1 | ||
| Microtubule-associated protein (Tau) | ||
| Serpin peptidase inhibitor, clade 1 (Neuroserpin), member 1 | ||
| Synuclein, alpha (non A4 component of amyloid precursor) | ||
| Cholesterol, LDL | Proprotein convertase Subtilisin/Kexin type 9 | |
| Low density lipoprotein receptor (familial hypercholesterolemia) | ||
| Apolipoprotein C-1 | ||
| Low density lipoprotein receptor adaptor protein 1 | ||
| Gallstones | Low density lipoprotein receptor-related protein associated Protein 1 | |
| Low density lipoprotein receptor (familial hypercholesterolemia) | ||
| Apolipoprotein C-1 | ||
| Macular degeneration, age-related | very low density lipoprotein receptor | |
| Microsomal Glutathione S-transferase 1 | ||
| Pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 1 | ||
| Colorectal cancer | Platelet-derived growth factor receptor-like | |
| V-HA-Ras Harvey rat sarcoma viral oncogene homolog | ||
| Mutated in colorectal cancers | ||
| Bladder cancer | V-HA-Ras Harvey rat sarcoma viral oncogene homolog | |
| Fibroblast growth factor receptor 3 ( Achondroplasia, Thanatophoric dwarfism) | ||
| Metabolic | Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) | |
| ATPase, class 1, Type 8B, member 1 | ||
| Heme oxygenase (decycling) 1 | ||
| Syndecan 2 (heparin sulfate proteoglycan 1, cell surface-associated, fibroglycan) | ||
| Bone morphogenetic protein 2 | ||
| Calmodulin 1 (Phosphorylase kinase, delta) | ||
| Hydatidiform mole associated and imprinted | ||
| Scavenger receptor class B, member 1 | ||
| Smad, mothers against DPP homolog 4 (Drosophila) | ||
| Metabolic | TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, psudoinflammatory) | |
| Fibrillin 1 (Marfan syndrome | ||
| Cardiovascular | Neural precursor cell expressed, developmentally downregulated 4-like | |
| Cyclin dependent kinase inhibitor 1C (p57, Kip2) | ||
| Caspase 1, Apoptosis-related Cysteine peptidase (Interleukin 1, beta, convertase) | ||
| Heme oxygenase (decycling) 1 | ||
| Calmodulin 1 (Phosphorylase kinase, delta) | ||
| Poliovirus receptor-related 2 (Herpesvirus entry mediator B) | ||
| Scavenger receptor class B, member 1 | ||
| TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, psudoinflammatory) | ||
The gene sets were investigated for potential link to diseases in a functional annotation analysis using DAVID. The disease states and the identity of genes potentially associated with it in the gene sets are presented.